MedTrace Logo

The Predicted Potential of Quantitative T Cell Repertoire(TCR) in Anti-PD-L1 Treatment in NSCLC Patients

NCT03228368 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2017-07-24

No results posted yet for this study

Summary

This study is designed to evaluate the predicted potential of quantitative T cell repertoire (TCR) of T cell receptor chains using next-generation sequencing (NGS) in the treatment of the anti-programmed death-ligand 1 (PD-L1) antibody atezolizumab in participants with locally advanced or metastatic NSCLC who have progressed during or following a platinum-containing regimen. Treatment may continue until disease progression or unacceptable toxicity.

Conditions

Interventions

DRUG

Atezolizumab (MPDL3280A)

anti-programmed death-ligand 1 (PD-L1) antibody

Sponsors & Collaborators

  • Hoffmann-La Roche

    collaborator INDUSTRY

  • Geneplus-Beijing Co. Ltd.

    collaborator INDUSTRY

  • First Affiliated Hospital of Zhejiang University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-01
Primary Completion
2018-03-01
Completion
2018-12-01
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03228368 on ClinicalTrials.gov